CymaBay Therapeutics (CBAY) – Research Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for CymaBay Therapeutics (NASDAQ: CBAY):

  • 4/17/2018 – CymaBay Therapeutics was given a new $20.00 price target on by analysts at Oppenheimer Holdings. They now have a “buy” rating on the stock.
  • 4/13/2018 – CymaBay Therapeutics had its price target raised by analysts at HC Wainwright to $21.00. They now have a “buy” rating on the stock.
  • 4/11/2018 – CymaBay Therapeutics had its price target raised by analysts at Leerink Swann from $16.00 to $20.00. They now have an “outperform” rating on the stock.
  • 4/11/2018 – CymaBay Therapeutics was given a new $18.00 price target on by analysts at Oppenheimer Holdings. They now have a “buy” rating on the stock.
  • 4/2/2018 – CymaBay Therapeutics was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 3/28/2018 – CymaBay Therapeutics is now covered by analysts at HC Wainwright. They set a “buy” rating and a $18.00 price target on the stock. They wrote, “EASL; Phase 3 Initiation in 2H18 on Track; Affirm Buy Stock Data 03/27/2018 Price $12.00 Exchange NASDAQ Price Target $18.00 52-Week High $15.59 52-Week Low $3.16 Enterprise Value (M) $611.7 Market Cap (M) $702 Public Market Float (M) 19.5 Shares Outstanding (M) 58.5 3 Month Avg Volume 980,454 Short Interest (M) 2.59 Balance Sheet Metrics Cash (M) $97.2 Total Debt (M) $6.9 Total Cash/Share $1.66 Book Value/Share $2.16 Cash (M): Amount shown is as of December 31 and does not include the $135.5M net proceeds from the recent equity raise.. EPS Diluted Full Year – Dec 2016A 2017A 2018E 1Q (0.29) (0.20) (0.21) 2Q (0.30) (0.31) (0.22) 3Q (0.25) (0.21) (0.25) 4Q (0.30) (0.11) (0.27) FY (1.14) (0.79) (0.95) Revenue ($M) Full Year – Dec 2016A 2017A 2018E 1Q 0.0 4.8 0.0 2Q 0.0 0.0 0.0 3Q 0.0 0.0 0.0 4Q 0.0 5.2 0.0 FY 0.0 10.0 5.0 20 15 10 5 0 MAR- 17 J UL- 17 NOV- 17 MAR- 18 12 10 8 6 4 2 0 Vol.””
  • 3/21/2018 – CymaBay Therapeutics had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings.
  • 3/16/2018 – CymaBay Therapeutics had its “buy” rating reaffirmed by analysts at SunTrust Banks. They now have a $19.00 price target on the stock.
  • 3/16/2018 – CymaBay Therapeutics had its “buy” rating reaffirmed by analysts at Piper Jaffray. They now have a $16.00 price target on the stock.
  • 3/16/2018 – CymaBay Therapeutics had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $16.00 price target on the stock. They wrote, “Clarity on Phase 3 PBC trial design should come before end of 2Q18. Management noted that discussions with U.S. and European regulators are ongoing and expressed pleasure with the level of engagement. Once the details have been finalized, the company expects to share them with the Street. High level, the company anticipates conducting a single pivotal study involving a treatment period of 12 months.””
  • 3/15/2018 – CymaBay Therapeutics was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 3/12/2018 – CymaBay Therapeutics was given a new $18.00 price target on by analysts at Oppenheimer Holdings. They now have a “buy” rating on the stock.
  • 2/21/2018 – CymaBay Therapeutics was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.

Shares of CBAY traded down $0.37 on Tuesday, reaching $12.75. 847,971 shares of the stock traded hands, compared to its average volume of 1,189,426. The stock has a market cap of $789.77, a PE ratio of -16.14 and a beta of 2.06. The company has a current ratio of 6.35, a quick ratio of 6.35 and a debt-to-equity ratio of 0.04. CymaBay Therapeutics has a 12 month low of $3.16 and a 12 month high of $15.59.

CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings data on Thursday, March 15th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.06. The firm had revenue of $5.20 million for the quarter, compared to the consensus estimate of $1.25 million. equities analysts forecast that CymaBay Therapeutics will post -0.89 earnings per share for the current fiscal year.

In related news, Director Carl Goldfischer sold 15,000 shares of the business’s stock in a transaction on Thursday, March 22nd. The stock was sold at an average price of $13.03, for a total value of $195,450.00. Following the sale, the director now owns 9,340 shares of the company’s stock, valued at approximately $121,700.20. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Kurt Von Emster sold 218,057 shares of the business’s stock in a transaction on Wednesday, February 14th. The shares were sold at an average price of $15.89, for a total value of $3,464,925.73. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 815,648 shares of company stock worth $10,283,751. 15.10% of the stock is currently owned by company insiders.

Hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp boosted its stake in CymaBay Therapeutics by 794.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 155,174 shares of the biopharmaceutical company’s stock valued at $1,251,000 after buying an additional 137,830 shares in the last quarter. Ameriprise Financial Inc. acquired a new stake in CymaBay Therapeutics in the 3rd quarter valued at $1,536,000. Farallon Capital Management LLC acquired a new stake in CymaBay Therapeutics in the 4th quarter valued at $10,120,000. Baird Financial Group Inc. boosted its stake in CymaBay Therapeutics by 26.8% in the 4th quarter. Baird Financial Group Inc. now owns 107,449 shares of the biopharmaceutical company’s stock valued at $989,000 after buying an additional 22,712 shares in the last quarter. Finally, Citadel Advisors LLC boosted its stake in CymaBay Therapeutics by 8.5% in the 4th quarter. Citadel Advisors LLC now owns 694,252 shares of the biopharmaceutical company’s stock valued at $6,387,000 after buying an additional 54,225 shares in the last quarter. 58.15% of the stock is currently owned by institutional investors and hedge funds.

Cymabay Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. It engages in developing seladelpar (MBX-8025), a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout.

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply